Literature DB >> 30896778

Comorbidities Associated with Severity of Atopic Dermatitis in Young Adult Males: A National Cohort Study.

Wai Leong Kok1, Yik Weng Yew, Tien Guan Thng.   

Abstract

Atopic dermatitis (AD) is a systemic inflammatory disorder. However, the relationship between severity of AD and metabolic and atopic conditions is not well studied. The aim of this study was to elucidate the relationship between severity of AD and comorbidities, such as metabolic conditions (increased body mass index, hypertension, hyperlipidaemia, and type II diabetes mellitus) and other atopic manifestations (allergic rhinitis, asthma and food allergies). A retrospective population-based national study of a cohort of young adult males conscripted into military service in Singapore over a 5-year period was performed, utilizing military electronic medical records. A dose-dependent effect was found between the association of comorbidities and severity of AD. Metabolic and atopic conditions were significantly correlated with having moderate-to-severe AD. An association of metabolic and atopic conditions with severity of adult AD was found, which suggests that chronic severe AD may result in increased disease burden and morbidity.

Entities:  

Keywords:  atopy; co-morbidities; eczema; metabolic; atopic dermatitis

Mesh:

Year:  2019        PMID: 30896778     DOI: 10.2340/00015555-3175

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

1.  Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study.

Authors:  A Campanati; T Bianchelli; R Gesuita; C Foti; G Malara; G Micali; P Amerio; F Rongioletti; M Corazza; A Patrizi; K Peris; N Pimpinelli; A Parodi; M C Fargnoli; S P Cannavo; P Pigatto; G Pellacani; S M Ferrucci; G Argenziano; F Cusano; G Fabbrocini; L Stingeni; M C Potenza; M Romanelli; L Bianchi; A Offidani
Journal:  Arch Dermatol Res       Date:  2021-06-07       Impact factor: 3.033

Review 2.  Dupilumab and COVID-19: What should we expect?

Authors:  Cataldo Patruno; Luca Stingeni; Gabriella Fabbrocini; Katharina Hansel; Maddalena Napolitano
Journal:  Dermatol Ther       Date:  2020-05-20       Impact factor: 2.851

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.